Skip to content
InMed-logo-01
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

In the Media

  • December 15, 2021

InMed Welcomes the BayMedica Team – Welcome Dr. Jim Kealey, VP of Synthetic Biology

InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Jim Kealey, our VP of Synthetic Biology.

Jim talks about his background in yeast and E.coli biosynthesis and applying his expertise in fermentation to overcome some of the supply challenges of producing enough product for testing of therapeutics. Jim and his BayMedica colleagues were the first to produce a lichen polyketide in yeast, which is relevant for the production of cannabinoids because the natural cannabinoid consists of a polyketide core structure.

Dr. Jim Kealey has an extensive background in biochemistry, molecular biology, enzymology and synthetic biology. He has focused his research efforts using these skills to engineer organisms, including yeast, to produce small molecules, pharmaceuticals, and biofuels. At Intrexon, Jim built and managed a large research team that developed pioneering methods and platforms to convert inexpensive methane into higher value products. His use of a Design-Build-Test-Learn approach allowed him to grow his cross-functional team to 30+ members while rapidly engineering molecules from proof of concept to pilot commercialization scale.

Jim was previously at Amyris where he and his colleagues were focused on the rapid engineering and development of S. cerevisiae to produce terpenes for industrial applications – (terpenes are common compounds in cannabis). While at Kosan Biosciences, Jim led groups that focused on the production of polyketides – a class of molecules that include anticancer, antibiotic and cannabinoids.

Jim earned a BA in Biochemistry & Molecular Biology of UC Santa Cruz and a PhD in Pharmaceutical Chemistry from UCSF.

Full Article
Source: Edison TV

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Latest Articles

The Dales Report – InMed Pharmaceuticals Unveils Industry Leading Portfolio

Jerry P. Griffin, VP of Sales and Marketing at BayMedica, InMed’s subsidiary, is interviewed by Shadd Dales of the The Dales Report to talk about

Read More
July 5, 2022

Pharma Tech Outlook: InMed Introduces THCV Into the Health and Wellness Industry

InMed’s THCV will bring ample opportunity to the health sector to scale up in the market. Read full story via Pharma Tech Outlook.

Read More
July 4, 2022

What are cannabinoid analogs?

Cannabinoid analogs are novel cannabinoid compounds that are slightly modified from the naturally occurring cannabinoids in the plant. Since they have a new molecular structure

Read More
July 3, 2022
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Cannabinoid Analogs
  • Cannabinoids in Development

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

  • Cannabidivarin (CBDV)
  • Tetrahydrocannabivarin (THCV)
  • Cannabichromene (CBC)
  • Cannabicitran (CBT)

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent